Shining More Light on RAS Inhibition during the COVID-19 Pandemic

Clin J Am Soc Nephrol. 2021 Jul;16(7):1002-1004. doi: 10.2215/CJN.06000521. Epub 2021 Jul 12.

Authors

Fitra Rianto¹, Matthew A Sparks^{1

2}

Affiliations

¹ Division of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.
² Renal Section, Durham Veterans Affairs Health Care System, Durham, North Carolina.

No abstract available

Keywords: ACE inhibitors; COVID-19; angiotensin; dialysis; kidney transplantation; mortality; virology.

Publication types

Editorial

MeSH terms

Angiotensin Receptor Antagonists / adverse effects*
Angiotensin-Converting Enzyme 2 / physiology*
Angiotensin-Converting Enzyme Inhibitors / adverse effects*
COVID-19 / etiology*
COVID-19 / mortality
Clinical Trials as Topic
Humans
SARS-CoV-2*
Severity of Illness Index

Substances

Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Angiotensin-Converting Enzyme 2